Figure 2.

(A) This figure illustrates the FDG-PET matched MIP and fused axial images with photographs at baseline and after receipt of cemiplimab of a 75-year-old male who had declined investigation and treatment of CSCC originating from his chin. After 18 months of pursuing alternative treatment, he accepted immunotherapy when the disease had become so advanced it mechanically impacted his ability to eat. He consented to participation in the NCT02760498, and after receipt of two doses clinical regression of the lesion was noted. His disease remains in complete remission after two years of therapy completed more than 12 months ago. (B) This figure illustrates re-epithelialization occurring during the receipt of compassionate access cemiplimab in a 45-year-old patient with more than a 20 year history of multiple NMSC including synchronous CSCC, BCC and MCC. The patient ceased vismodegib to commence cemiplimab on 13/DEC/2019 but required recommencement of vismodegib on 19/APR/2020 due to recurrence of multiple BCC lesions. He remains on dual therapy given the symptomatic improvement achieved with good pain control and resolution of right cheek CSCC-related trismus.